Table 5:
Ratio of observed-to-expected rates of myocarditis among males following mRNA SARS-CoV-2 vaccination*
| Risk window | Vaccine | Age group, yr | OE ratio (95% CI) | |||
|---|---|---|---|---|---|---|
| All doses | Dose 1 | Dose 2 | Dose 3 | |||
| 7 days | Pfizer | 12–17 | 95.59 (53.5–157.66) | 42.56 (8.78–124.38) | 134.29 (61.41–254.93) | 139.80 (28.83–408.55) |
| 18–29 | 16.98 (9.89–27.19) | 2.45 (0.06–13.66) | 34.05 (18.13–58.23) | 20.02 (4.13–58.50) | ||
| 30–39 | 3.94 (0.81–11.51) | 3.13 (0.08–17.45) | 3.35 (0.08–18.68) | 11.84 (0.30–65.95) | ||
| 40–49 | 5.80 (0.70–20.94) | 0.00 (0.00–27.54) | 8.05 (0.20–44.85) | 25.51 (0.65–142.11) | ||
| 50–59 | 6.85 (0.83–24.74) | 0.00 (0.00–33.4) | 20.05 (2.43–72.45) | 0.00 (0.00–100.90) | ||
| 60–69 | 4.01 (0.10–22.32) | 0.00 (0.00–38.59) | 12.10 (0.31–67.40) | 0.00 (0.00–102.01) | ||
| 70–79 | 0.00 (0.00–11.15) | 0.00 (0.00–29.43) | 0.00 (0.00–32.29) | 0.00 (0.00–64.13) | ||
| ≥ 80 | 10.45 (1.26–37.73) | 0.00 (0.00–61.02) | 35.25 (4.27–127.32) | 0.00 (0.00–130.95) | ||
| Moderna | 12–17 | NA | NA | NA | NA | |
| 18–29 | 71.44 (46.67–104.68) | 6.08 (0.15–33.87) | 148.32 (95.03–220.69) | 26.58 (0.67–148.11) | ||
| 30–39 | 20.55 (8.87–40.50) | 0.00 (0.00–27.75) | 50.77 (20.41–104.6) | 8.45 (0.21–47.06) | ||
| 40–49 | 6.07 (0.15–33.80) | 0.00 (0.00–71.62) | 18.08 (0.46–100.73) | 0.00 (0.00–63.56) | ||
| 50–59 | 6.69 (0.17–37.26) | 23.61 (0.60–131.53) | 0.00 (0.00–75.52) | 0.00 (0.00–63.26) | ||
| 60–69 | 0.00 (0.00–27.28) | 0.00 (0.00–114.68) | 0.00 (0.00–87.46) | 0.00 (0.00–60.58) | ||
| 70–79 | 12.78 (1.55–46.17) | 0.00 (0.00–118.33) | 0.00 (0.00–89.82) | 23.74 (2.88–85.77) | ||
| ≥ 80 | 0.00 (0.00–47.39) | 0.00 (0.00–232.48) | 0.00 (0.00–188.82) | 0.00 (0.00–86.93) | ||
| 21 days | Pfizer | 12–17 | 36.11 (21.04–57.82) | 18.92 (5.15–48.43) | 44.76 (20.47–84.98) | 62.13 (16.93–159.08) |
| 18–29 | 6.66 (4.07–10.28) | 1.63 (0.20–5.91) | 13.10 (7.33–21.60) | 6.67 (1.38–19.50) | ||
| 30–39 | 4.81 (2.40–8.62) | 6.26 (2.30–13.63) | 3.35 (0.69–9.80) | 7.89 (0.96–28.50) | ||
| 40–49 | 3.86 (1.05–9.89) | 2.49 (0.06–13.87) | 5.37 (0.65–19.38) | 8.50 (0.22–47.37) | ||
| 50–59 | 5.71 (1.85–13.32) | 6.04 (0.73–21.8) | 6.68 (0.81–24.15) | 9.12 (0.23–50.80) | ||
| 60–69 | 2.67 (0.32–9.65) | 0.00 (0.00–12.86) | 4.03 (0.10–22.47) | 9.22 (0.23–51.36) | ||
| 70–79 | 0.00 (0.00–3.72) | 0.00 (0.00–9.81) | 0.00 (0.00–10.76) | 0.00 (0.00–21.38) | ||
| ≥ 80 | 3.48 (0.42–12.58) | 0.00 (0.00–20.34) | 11.75 (1.42–42.44) | 0.00 (0.00–43.65) | ||
| Moderna | 12–17 | NA | NA | NA | NA | |
| 18–29 | 24.73 (16.30–35.98) | 2.03 (0.05–11.29) | 51.50 (33.33–76.03) | 8.86 (0.22–49.37) | ||
| 30–39 | 8.56 (4.11–15.75) | 5.01 (0.61–18.11) | 16.92 (6.80–34.87) | 2.82 (0.07–15.69) | ||
| 40–49 | 2.02 (0.05–11.27) | 0.00 (0.00–23.87) | 6.03 (0.15–33.58) | 0.00 (0.00–21.19) | ||
| 50–59 | 4.46 (0.54–16.11) | 15.74 (1.91–56.85) | 0.00 (0.00–25.17) | 0.00 (0.00–21.09) | ||
| 60–69 | 2.46 (0.06–13.73) | 0.00 (0.00–38.23) | 0.00 (0.00–29.15) | 5.47 (0.14–30.50) | ||
| 70–79 | 4.26 (0.52–15.39) | 0.00 (0.00–39.44) | 0.00 (0.00–29.94) | 7.91 (0.96–28.59) | ||
| ≥ 80 | 4.28 (0.11–23.86) | 0.00 (0.00–77.49) | 0.00 (0.00–62.94) | 7.86 (0.20–43.77) | ||
Note: CI = confidence interval, Moderna = mRNA-1273 (Moderna), NA = not applicable, OE = observed-to-expected, Pfizer = BNT162b2 (Pfizer-BioNTech).
*
Observed rates of myocarditis were calculated per 100 000 vaccine doses. Expected rates of myocarditis were expressed per 100 000 population.